Drug Patent, Regulatory Exclusivity, and other protection rights (PTA & PTE and SPC) in Pharmaceuticals Development in US and Europe
Abstract
Understanding eligibility for drug patents and exclusivity is essential for protecting innovations in the competitive pharmaceutical sector. When a pharmaceutical company develops a new drug, a patent protects this invention from unauthorized use, ensuring that the inventor can recoup the research and development costs throughout the product’s lifecycle.
This article discusses the various types of protections for pharmaceutical products granted by intellectual property offices and regulatory authorities, highlighting the differences and similarities between the United States and Europe. By demonstrating the patent protections and regulatory exclusivity, the article provides insights into the specific country’s regulations and criteria that must be met to obtain the patent and the exclusivity rights.
In the United States, there are Patent Term Adjustment (PTA) and Patent Term Extension (PTE and in Europe, there is the Supplementary Protection Certificate (SPC). This article illustrates these protection rights and compares their main features. Additionally, it presents straightforward scenarios that outline the key elements influencing the determination and calculation of the protection period, as well as the timely launch of products into the market.
Downloads
References
https://www.rstreet.org/commentary/the-economics-of-drug-discovery-and-the-impact-of-patents/
2. Sertkaya A, Beleche T, Jessup A, Sommers B.D. Costs of Drug Development and Research and Development Intensity in the US. 2000-2018. JAMA Network Open; 2024;7(6):e2415445.
doi:10.1001/jamanetworkopen.2024.15445
3. Spencer D. Europe: Where is the drug discovery innovation? [Internet]. DDW;2024 May 6; [cited 2025 Mar 5]. Available from:
https://www.ddw-online.com/europe-where-is-the-drug-discovery-innovation-29479-202405/
4. Mandal A. Drug Patents and Generic Pharmaceutical Drugs [Internet]. News Medical Life Sciences; 2023 Jun 15[cited 2025 Feb12]. Available from: https://www.news-medical.net/health/Drug-Patents-and-Generics.aspx
5. Types of Marketing Exclusivity in Drug Development [Internet]. Allucent [cited 2025 Jan 20] Available from:
https://www.allucent.com/resources/blog/types-marketing-exclusivity-drug-development#:~:text=Unlike%20a%20patent%2C%20which%20is,when%20statutory%20requirements%20are%20met
6. Pistilli T. Pharmaceutical Patent Regulation in the United States [Internet]. The Society of Actuaries, Chicago, Illinois; 2021 Feb[cited 2025 Jan 3]. Available from:
https://www.theactuarymagazine.org/pharmaceutical-patent-regulation-in-the-united-states/
7. Lal R. Patents and Exclusivity [Internet]. FDA/CBER SBIA Chronicles,CBER Small Bussiness and Industry Assistance (SBIA);2015 May 19[cited 2025 Mar 21].Available from: https://www.fda.gov/media/92548/download
8. Article 63 Term of the European Patent [Internet]. The European Patent Office; 2020 Jul 1[cited 2025 Feb 15]. Available from:
https://www.epo.org/en/legal/epc/2016/a63.html
9. How you register a patent [Internet]. Your Europe; 2025 Jan 28 [cited 2025 Mar 7]. Available from:
https://europa.eu/youreurope/business/running-business/intellectual-property/patents/index_en.htm#inline-nav-3
10. Unitary Patent [Internet]. The European Commission; 2024 Aug [cited 2025 Mar 16]. Available from:
https://www.epo.org/en/applying/european/unitary/unitary-patent
11. Supplementary protection certificates for pharmaceutical and plant protection products [Internet]. The European Commission [cited 2025 Mar 13]. Available from:
https://single-market-economy.ec.europa.eu/industry/strategy/intellectual-property/patent-protection-eu/supplementary-protection-certificates-pharmaceutical-and-plant-protection-products_en
12. Tran B. 10 Key Differences Between U.S. and European Patent Systems [Internet]. Patent PC; 2025 April 14[cited 2025 April 23]. Available from:
https://patentpc.com/blog/10-key-differences-between-u-s-and-european-patent-systems
13. Sharma G, Jindal H. Exploring Delay Categories, Calculation, and Best Practices [Internet]. Sagacious Elevate [cited 2025 Mar 22].Available from:
https://sagaciousresearch.com/blog/navigating-patent-term-adjustment-exploring-delay-categories-calculation-and-best-practices/
14. Vincent N G. Patent term extension and the active ingredient problem. JIPEL.2020;9(2)281.
15. Mahn T G, Murphy T. Introduction to Patent Term Extensions (PTE) [Internet]. Fish & Richardson P.C; 2020 Jul 31 [cited 2024 Dec 16]. Available from:
https://www.fr.com/insights/ip-law-essentials/intro-patent-term-extension/
16. Murhpy J. Patent Term Extensions and Market Exclusivity) [Internet]. Stratagem; 2015 Jul 24 [cited 2025 Jan 19]. Available from:
https://www.stratagemipm.co.uk/news/patent-term-extensions-and-market-exclusivity/
17. Carridge A. The Drug Exclusivity Landscape in Europe [Internet]. Reddie & Grose LLP; 2021 Aug 3 [cited 2025 Feb 1]. Available from:
https://www.reddie.co.uk/2021/08/03/the-drug-exclusivity-landscape-in-europe/
18. Protection beyond 20 years: data on SPCs and other term extensions for pharmaceutical patents [Internet]. The European Patent Office; 2024 April 22 [cited 2025 Feb 4]. Available from:
https://www.epo.org/en/searching-for-patents/helpful-resources/patent-knowledge-news/protection-beyond-20-years-data-spcs
19. Thomas JR. Regulatory Exclusivity Reform in the 115th Congress [Internet]. EveryCRSReport.com; 2017 Sept 15 [cited 2024 Dec 21]. Available from:
https://www.everycrsreport.com/reports/R44951.html#_Toc493593794
20. Patel R. Exclusivity–Which one is for me? [Internet]. USFDA [cited 2025 Mar 24 ]. Available from:
https://www.fda.gov/media/135234/download
21. Data & Market Exclusivity As Incentives in Drug Development [Internet]. Scendea Ltd; 2020 Dec [cited 2025 Feb 8 ]. Available from:
https://www.scendea.com/articles/blog-post-title-one-25srn-58l3m-hef63#:~:text=Market%20exclusivity%20refers%20to%20the%20period%20of%20time,on%20the%20basis%20of%20the%20innovator%E2%80%99s%20data%20package.
22. Exclusivity for pharmaceutical products [Internet]. MedCity;2023 Jun 27 [cited 2025 Feb 3]. Available from:
https://medcityhq.com/2023/06/27/exclusivity-for-pharmaceutical-products/
23. Praveen KB. Patent and Exclusivity [Internet]. Pharma Focus Asia; 2020 [cited 2025 Jan 14 ]. Available from: https://www.pharmafocusasia.com/strategy/patents-and-exclusivity
24. Oronsky B, Caroen S, Brinkhaus F, Reid T, Stirn M, Kumar R. Patent and Marketing Exclusivities 101 for Drug Developers. Bentham Science; 2023;17(3):257-270.
doi: 10.2174/1872208317666230111105223.
25. Data Exclusivity and Market Protection in the EU / EEA and UK [Internet]. J A Kemp; 2023 Sept 5 [cited 2025 Feb 9 ]. Available from:
https://jakemp.com/en/briefings/data-exclusivity-and-market-protection-in-the-eu-eea-and-uk/
26. Market exclusivity: orphan medicines [Internet]. European Medicines Agency;2025 [cited 2025 Jan 5]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/orphan-designation-post-authorisation/market-exclusivity-orphan-medicines#external-links-17839
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
